EVAMIST Drug Patent Profile
✉ Email this page to a colleague
When do Evamist patents expire, and when can generic versions of Evamist launch?
Evamist is a drug marketed by Padagis Us and is included in one NDA.
The generic ingredient in EVAMIST is estradiol. There are seventy-five drug master file entries for this compound. Forty-five suppliers are listed for this compound. Additional details are available on the estradiol profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Evamist
A generic version of EVAMIST was approved as estradiol by BARR LABS INC on October 22nd, 1997.
Summary for EVAMIST
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 109 |
| Clinical Trials: | 1 |
| Patent Applications: | 4,323 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for EVAMIST |
| Drug Sales Revenues: | Drug sales revenues for EVAMIST |
| What excipients (inactive ingredients) are in EVAMIST? | EVAMIST excipients list |
| DailyMed Link: | EVAMIST at DailyMed |
Recent Clinical Trials for EVAMIST
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Lumara Health, Inc. | Phase 3 |
Pharmacology for EVAMIST
| Drug Class | Estrogen |
| Mechanism of Action | Estrogen Receptor Agonists |
Anatomical Therapeutic Chemical (ATC) Classes for EVAMIST
US Patents and Regulatory Information for EVAMIST
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Padagis Us | EVAMIST | estradiol | SPRAY;TRANSDERMAL | 022014-001 | Jul 27, 2007 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for EVAMIST
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Padagis Us | EVAMIST | estradiol | SPRAY;TRANSDERMAL | 022014-001 | Jul 27, 2007 | ⤷ Try a Trial | ⤷ Try a Trial |
| Padagis Us | EVAMIST | estradiol | SPRAY;TRANSDERMAL | 022014-001 | Jul 27, 2007 | ⤷ Try a Trial | ⤷ Try a Trial |
| Padagis Us | EVAMIST | estradiol | SPRAY;TRANSDERMAL | 022014-001 | Jul 27, 2007 | ⤷ Try a Trial | ⤷ Try a Trial |
| Padagis Us | EVAMIST | estradiol | SPRAY;TRANSDERMAL | 022014-001 | Jul 27, 2007 | ⤷ Try a Trial | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for EVAMIST
See the table below for patents covering EVAMIST around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Germany | 122012000020 | ⤷ Try a Trial | |
| Australia | 2035202 | ⤷ Try a Trial | |
| Japan | 2004513755 | ⤷ Try a Trial | |
| Luxembourg | 91973 | ⤷ Try a Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for EVAMIST
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0901368 | CA 2012 00010 | Denmark | ⤷ Try a Trial | |
| 1380301 | 2009C/007 | Belgium | ⤷ Try a Trial | PRODUCT NAME: DROSPIRENONE-ETHINYLESTRADIOL; AUTHORISATION NUMBER AND DATE: BE321386 20080811 |
| 0771217 | 07C0001 | France | ⤷ Try a Trial | PRODUCT NAME: ETHINYLESTRADIOL BETADEX CLATHRATE; NAT. REGISTRATION NO/DATE: NL 32343 20060710; FIRST REGISTRATION: NL - RVG 31781 20050804 |
| 0770388 | PA2009004,C0770388 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: ESTRADIOLI VALERAS + DIENOGESTUM; NAT. REGISTRATION NO/DATE: LT/1/09/1512/001, 2009 04 06 LT/1/09/1512/002, 2009 04 06 LT/1/09/1512/003 20090406; FIRST REGISTRATION: BE 327792 20081103 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
